Robert E. Landry

2020

In 2020, Robert E. Landry earned a total compensation of $6.2M as Executive Vice President, Finance and Chief Financial Officer at Regeneron Pharmaceuticals, a 22% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$938,872
Option Awards$3,459,499
Salary$825,577
Stock Awards$949,560
Other$24,195
Total$6,197,703

Landry received $3.5M in option awards, accounting for 56% of the total pay in 2020.

Landry also received $938.9K in non-equity incentive plan, $825.6K in salary, $949.6K in stock awards and $24.2K in other compensation.

Rankings

In 2020, Robert E. Landry's compensation ranked 1,665th out of 13,090 executives tracked by ExecPay. In other words, Landry earned more than 87.3% of executives.

ClassificationRankingPercentile
All
1,665
out of 13,090
87th
Division
Manufacturing
631
out of 5,621
89th
Major group
Chemicals And Allied Products
229
out of 2,254
90th
Industry group
Drugs
192
out of 1,954
90th
Industry
Pharmaceutical Preparations
133
out of 1,459
91st
Source: SEC filing on April 23, 2021.

Landry's colleagues

We found four more compensation records of executives who worked with Robert E. Landry at Regeneron Pharmaceuticals in 2020.

2020

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer

2020

George Yancopoulos

Regeneron Pharmaceuticals

Chief Scientific Officer

2020

Andrew Murphy

Regeneron Pharmaceuticals

Executive Vice President, Research

2020

Daniel Van Plew

Regeneron Pharmaceuticals

Executive Vice President and General Manager, Industrial Operations and Product Supply

News

In-depth

You may also like